INTRODUCTION
The usefulness of dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM) is widely known in Japan.
While combination therapy with insulin injections and a DPP-4 inhibitor has been investigated in clinical studies [1, 2] , to date only a few reports have discussed the usefulness and safety over a long treatment period [3] .
Insulin regimens used in the management of T2DM include long-acting insulin given once daily, premixed insulin given twice or thrice daily, and multiple daily insulin injections (basal-bolus therapy), as well as a variety of regimens combining insulin and oral antidiabetic drugs. In insulin-treated patients with T2DM, the duration of diabetes is longer and hypo-secretion of endogenous insulin is common, but their clinical characteristics are not homogeneous. Therefore, the authors considered that prospective clinical studies should be conducted to identify the patient populations which would benefit from concomitant treatment with insulin and a DPP-4 inhibitor. The authors have previously reported the short-term results of add-on therapy with sitagliptin in patients with T2DM receiving insulin, who were assessed prospectively for 12 weeks [4] . In this study, the medium-term results of the add-on therapy with sitagliptin up to 48 weeks was evaluated by follow-up of the same patient population to monitor glycemic control, insulin dosage, concomitant drugs, body weight, and adverse events. The objective of this study was to investigate whether the combination therapy maintains good glycemic control for 48 weeks with acceptable safety.
METHODS
The patients with T2DM recruited for this study were treated at Hyogo College of Medicine and Ikeda Hospital from September 2011 to June 2013, and fulfilled the following eligibility criteria. Inclusion criteria for this study were as follows: (1) 
severe hypoglycemia or recurrent asymptomatic hypoglycemia, (4) severe infection, (5) patients scheduled for surgery or those with severe trauma, (6) pregnant or nursing women and women who could possibly become pregnant, and (7) other patients whom the investigator judged to be inappropriate for the study.
The study protocol was reviewed and approved by the Ethics Committee of Hyogo College of Medicine. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients before inclusion in the study. All subjects were given an explanation of the details of the study and voluntarily gave written informed consent to participation. After completion of the 12-week study, informed consent was again obtained to continue administration of sitagliptin.
Patients who fulfilled the above eligibility criteria continued to receive the add-on therapy with sitagliptin 50 mg given once daily after breakfast for 48 weeks. Throughout the study period, in patient instruction, emphasis was placed on avoiding hypoglycemic episodes based on data obtained by self-monitoring of blood glucose.
The primary endpoint was changes in HbA1c up to 48 weeks. HbA1c, blood glucose, and body weight were measured every 4 weeks. In addition, serum C-peptide reactivity index (CPI) was measured at weeks 0, 12, 24, and 48.
Adverse events were monitored throughout the study period.
Statistical Analysis
Changes in HbA1c during sitagliptin treatment were analyzed by one-way analysis of variance. 
RESULTS
After exclusion of 1 patient who discontinued treatment after completing week 12, 70 patients were included in this study. Another patient was transferred to a different hospital during the study, therefore 69 patients completed the 48-week observation period. 
Overall Results

Patient Characteristics
Changes in HbA1c
Changes in HbA1c were the primary endpoint of this study. HbA1c decreased significantly from 8.03 ± 1.07% at week 0 (at the time of initiation of the add-on therapy) to 7.51 ± 0.91% after 12 weeks (P\0.01),
7.59 ± 1.09% after 24 weeks (P\0.05), and 7.45 ± 1.03% after 48 weeks (P\0.01; Fig. 1 ). sulfonylureas. These drugs were discontinued in two patients (4.8%), the daily dose was decreased in 10 patients (23.8%) and increased in three patients (7.1%), and the sulfonylurea dosage was not changed in other patients.
Changes in Other Parameters
Severe Hypoglycemia and Adverse Events
None of the patients experienced severe hypoglycemia that required assistance by a third party or treatment including intravenous infusion. In addition, none of the patients discontinued the administration of sitagliptin due to an adverse event.
Stratified Analysis by Patient Characteristics
Evaluation of Patients Responding to the Add-On Therapy
To identify patients for whom the add-on therapy with sitagliptin showed high efficacy, correlations between the hypoglycemic effect (change in HbA1c from week 0 to week 48) and various baseline characteristics were evaluated; a high baseline HbA1c was identified as a factor that was significantly associated with the decrease in HbA1c (r = -0.29249, P = 0.00180; Table 3 ).
Influence of Specific Factors
The influences of specific baseline factors (age, BMI, CPI, and oral hypoglycemic agents) on changes in HbA1c after 48 weeks were investigated by stratifying patients as shown in Fig. 2 For all factors, the stratified groups showed a significant decrease in HbA1c, but no significant difference was found between the groups (Fig. 2) .
Stratified Analysis by Insulin Regimen
Profile of the Three Insulin Regimen Groups
The insulin regimen was twice daily injection of premixed insulin in 45 patients (64.3%, twice daily group), multiple daily injections of insulin in 14 patients (20.0%, multiple injections group), and basal insulin therapy in 11 patients (15.7%, basal insulin group). Table 4 shows the baseline characteristics of each group.
Changes in HbA1c by Insulin Regimens
HbA1c decreased significantly after 48 weeks in all three groups; there was no significant BMI body mass index, CPI C-peptide reactivity index, HbA1c hemoglobin A1c difference between the three insulin regimens (Fig. 3) . Table 5 shows changes in other parameters by three insulin regimens. For all parameters (body weight, CPI, and insulin dosage), there was no significant difference between the three insulin regimens in terms of changes in parameters from baseline to week 48.
Changes in Other Parameters by Insulin Regimens
DISCUSSION
In this study that investigated the effects of the combination therapy of sitagliptin and insulin in 70 Japanese patients with T2DM, there were four main findings: (1) The insulin dosage was reduced significantly after 48 weeks without weight gain; (2) HbA1c was decreased by 0.58% after 48 weeks compared with the baseline value; (3) There were no problematic adverse events, including severe hypoglycemia; and (4) Mean SD, Paired t-test (vs baseline) requires a long-term treatment. Therefore, the patients from our previous study were followed up to week 48 in this study. The authors found that HbA1c was still significantly lower than the baseline level after 48 weeks, while there was no change in body weight compared to the baseline level. Also, no serious adverse event was observed during the 48-week observation period; thus, the results of the present study confirmed those of the previous short-term study. Some previous studies have evaluated the effects of add-on therapy of sitagliptin in insulin-treated patients. In a randomized controlled study that compared an ongoing insulin therapy group (twice daily or more) with a sitagliptin add-on group (50 mg or 100 mg/day) in 50 Japanese patients with T2DM, a significant reduction in HbA1c and reduced insulin dosage was observed after 24 weeks in the sitagliptin add-on group [7] .
There is also an observational study that investigated the effects of combination therapy of sitagliptin and insulin in Japanese patients with T2DM receiving different insulin regimens [8] . To date, the influence of sitagliptin on the insulin dosage had not been fully evaluated in Japanese patients because sitagliptin is administered in combination with a fixed dose of insulin (mainly twice daily premixed insulin). This study showed that the insulin dosage was significantly reduced after 48 weeks of the add-on therapy with sitagliptin. Among the 42 patients also receiving treatment with sulfonylureas, the sulfonylurea dosage was increased in only three patients, while it was decreased in 10 patients and sulfonylureas were discontinued in two patients. Moreover, CPI was significantly higher than baseline after 48 weeks of the add-on therapy with sitagliptin, indicating that endogenous insulin secretion was maintained and even improved. Therefore, the stable hypoglycemic effect were significantly improved, and that diurnal variation of blood glucose was improved along with inhibition of postprandial hyperglycemia.
The possibility was suggested that adding sitagliptin to twice daily premixed insulin could improve postprandial blood glucose [10] . In the twice daily group and basal insulin group in the current study, postprandial hyperglycemia had not been satisfactorily controlled prior to combined therapy, but it was improved by add-on sitagliptin; also, HbA1c decreased during the relatively short period of 12 weeks. However, the authors consider that further improvement of HbA1c over time is not likely in these patients, and other treatment will be needed. Table 5 , the change in CPI was largest in the basal insulin group, followed by the multiple injections group. Nevertheless, a significant increase in CPI was observed only in the twice daily group. This may be because of the small number of patients in the multiple injections group, causing insufficient power to detect a significant difference.
Dipeptidyl peptidase-4 inhibitors have both a glucose-dependent insulinotropic effect and a glucagonostatic effect, which contribute equally to the glucose-lowering action of these drugs [11] . Sitagliptin has been reported to reduce blood glucose in patients with type 1 diabetes treated with insulin [12] , and a glucagonostatic effect of glucagon-like peptide-1 receptor agonists was also reported in patients with type 1 diabetes [13] . In patients with impaired endogenous insulin secretion, it is probable that the glucagonostatic effect could be more important than the improvement of endogenous insulin secretion soon after initiation of sitagliptin treatment, while a blood glucose-lowering effect similar to that in patients with CPI C0.8 was seen after 48 weeks owing to improvement of insulin secretion over time as a result of the suppression of glucotoxicity.
It should be noted that the glucose-lowering efficacy of DPP-4 inhibitors may be greater in Asian populations including Japanese [14] , thus, the results of the present study may be different in Western populations. In terms of the effects of sitagliptin in Caucasians, a large-scale randomized, double-blind, placebo-controlled, 24-week clinical trial in which treatment with sitagliptin 100 mg/day or placebo was administered concurrently with insulin glargine titration has been conducted [15] . The present study is similar to this study in that, the add-on therapy with sitagliptin led to a decrease in HbA1c, decreased insulin dosage and reduced hypoglycemia incidence. However, unlike the present study, the insulin therapy was limited to insulin glargine. The authors believe that the present study is beneficial as it determined the add-on effects of sitagliptin given over a longer time with different types of insulin regimens.
CONCLUSIONS
In conclusion, add-on therapy with sitagliptin maintained stable glycemic control for 48 weeks without weight gain or problematic adverse events in patients with poor baseline glycemic control despite various insulin regimens. The authors' finding that endogenous insulin secretion was increased after 48 weeks compared with that measured at the initiation of the add-on therapy suggests that long-term treatment may be beneficial. However, a randomized controlled trial is necessary to confirm these results.
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